Brief summary

This is a multi­centre, single-blind, prospective randomized investigator-driven trial that will include 2100 patients in 10 countries. Included patients will present a high-risk for restenosis due to clinical profile or coronary lesion complexity and will undergo elective 

or emergent percutaneous coronary intervention.

Once included in the study, patient will receive either Absorb scaffold or Xience stent and will be followed 

for 5 years.

The results of this study will help to assess the non­inferiority of the everolimus­eluting bioresorbable scaffold (BRS) to the everolimus eluting cobalt chromium metallic stent (EES) in 

target lesion failure(TLF) at 1 year and the superiority of the BRS to the EES in TLF between 1 and 5 


Primary endpoints

  • Target lesion failure (TLF) as defined as a composite of
    • Cardiac death
    • Myocardial infarction (MI) in target vessel territory (SCAI consensus for periprocedural MI, 3rd universal definition for spontaneous or other MI)
    • Clinically Indicated Target lesion revascularization

CERC Services

  • Regulatory Submissions
  • Project management
  • Contract Managment
  • Monitoring
  • Data Management
  •  AE Reporting
  • Organization of DSMB


  • Belgium
  • Czech Republic
  • France
  • Germany
  • Italy
  • Netherlands
  • Poland
  • Spain
  • Switzerland
  • United Kingdom

Center number

49 centers managed by CERC.